Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Allergan

Status and phase: Completed; Phase 4

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: latanoprost 0.005% eye drops; Drug: bimatoprost 0.03% eye drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT00541242

192024-034

Details and patient eligibility

About

The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Enrollment: 586 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ocular hypertension or chronic glaucoma
• Patient requires IOP-lowering therapy in both eyes

Exclusion criteria

• Uncontrolled medical conditions
• Hypersensitivity to study medications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

586 participants in 2 patient groups

1

Active Comparator group

Description:

bimatoprost 0.03% eye drops

Treatment:

Drug: bimatoprost 0.03% eye drops

2

Active Comparator group

Description:

latanoprost 0.005% eye drops

Treatment:

Drug: latanoprost 0.005% eye drops